China News Weekly 116 – Chinese electric automaker BYD opens first plant in Canada

China News Weekly 116 – Chinese electric automaker BYD opens first plant in Canada

Click here to find more details This is NAI’s new China News Weekly. We will be covering the latest Chinese foreign investment trends every week. To continue to receive our China News Weekly, please click Here to subscribe.

Read more
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces on June 24, 2019, that the first patient has...

Read more
AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses...

Read more
Sinopharm Leads $20 Million Investment in Singapore’s Novena; Plans Joint $150 Million Healthcare Fund

Sinopharm Leads $20 Million Investment in Singapore’s Novena; Plans Joint $150 Million Healthcare Fund

Novena Global Lifecare, a Singapore company with 250 aesthetic clinics and sales outlets in southeast Asia, will receive an investment of up to $20 million from Sinopharm Capital and Cedarlake Capital. Founded in 2010, Novena is one of the...

Read more
Eli Lilly Unit Selects China’s Amoy Diagnostics’ Gene Products for Cancer Drug

Eli Lilly Unit Selects China’s Amoy Diagnostics’ Gene Products for Cancer Drug

China’s Amoy Diagnostics will partner with Loxo Oncology, a developer of targeted cancer drugs owned by Eli Lilly and Company, to supply it with accompanying reagents for genetic diagnosis during clinical trials of new drugs in Asia. The...

Read more
Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US and China while...

Read more
Eddingpharm In-Licenses Shionogi Thrombocytopenia Treatment

Eddingpharm In-Licenses Shionogi Thrombocytopenia Treatment

Eddingpharm in-licensed greater China rights to a treatment for thrombocytopenia, a side-effect of liver disease, from Shionogi of Japan. People with thrombocytopenia suffer from a low platelet count and are usually treated with via blood...

Read more
dMed, a Shanghai Clinical CRO, Opens Washington Office for US FDA Filings

dMed, a Shanghai Clinical CRO, Opens Washington Office for US FDA Filings

dMed Biopharma, a Shanghai clinical CRO, has opened a Washington office to help China biopharmas complete their US regulatory filings. Since 2017, China’s harmonization with the regulatory systems of other countries revolutionized the...

Read more
Chi-Med’s Surufatinib Meets Survival Endpoint — Trial Stopped Early

Chi-Med’s Surufatinib Meets Survival Endpoint — Trial Stopped Early

Hutchison China MediTech (Chi-Med) will stop its Phase III trial of surufatinib early following positive interim data showing the candidate met its primary endpoint of progression-free survival. The China trial was testing surufatinib in patients...

Read more
Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia

Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia

Jiangsu Hengrui Medicine in-licensed greater China rights to a treatment for chronic yeast infections from Mycovia Pharma of Durham, North Carolina. Mycovia is currently conducting a Phase III trial of VT-1161 (otesaconazole) in women with...

Read more
Hansoh Completes $1 Billion Hong Kong IPO; Rises 37% in First Trading Session

Hansoh Completes $1 Billion Hong Kong IPO; Rises 37% in First Trading Session

Hansoh Pharma completed a highly successful Hong Kong IPO, pricing last week at the top end of its range, and then following up with a 37% rise in its first trading session today. The IPO raised $1 billion for the company at a valuation of $10.7...

Read more
Reistone Starts Global Trial of China-Discovered JAK1 Inhibitor for IBD

Reistone Starts Global Trial of China-Discovered JAK1 Inhibitor for IBD

Reistone, a one-year-old Shanghai-Beijing-Boston biopharma, has dosed the first patient in global Phase II trial of its JAK1 inhibitor in patients with Ulcerative Colitis and Crohn’s disease. The JAK1 candidate was developed by Jiangsu...

Read more
Do NOT follow this link or you will be banned from the site!